(CDAX, Technology, SMHN GR)



Buy eur 30.00		Value Indicators: DCF: FCF-Value Potential 24e:	30.00	Warburg ESG Risk Score: ESG Score (MSCI based): Balance Sheet Score: Market Liquidity Score:	2.3 3.0 2.0 2.0	Description: Leading solution provider for markets advanced packaging integration, LED, MEMS	
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2022e
		Market cap:	383.9	Freefloat 1	00.00 %	Beta:	1.3
Price	EUR 20.10	No. of shares (m):	19.1	Universal Investment	9.60 %	Price / Book:	2.2 x
Upside	49.3 %	EV:	323.5	Luxempart	8.30 %	Equity Ratio:	52 %
		Freefloat MC:	383.9	Teslin	6.70 %		
		Ø Trad. Vol. (30d):	829.76 th	Henderson	5.00 %		

2023 guidance due next week

Expected Fig	gures Q4	4/2022:					Comment on Figures:
FY End: 31.12. in EUR m	Q4 22e	Q4 21	уоу	22e	21	уоу	 SÜSS already released preliminary 2022 results earlier in th reached the high end of the guidance
Order entry Sales EBIT Margin EBIT adj. Margin	71.5 104.8 20.4 19.5 % 17.6 16.8 %	82.0 74.9 4.8 6.4 % 4.8 6.4 %	-13 % 40 % 323 % 265 %	445.0 300.0 31.4 10.5 % 28.6 9.5 %	335.6 263.4 22.6 8.6 % 22.6 8.6 %	33 % 14 % 39 % 27 %	 SÜSS recorded a positive one-off of EUR 2.8m from the closs subsidiary in Q4 (scanners, which have been relocated to Ta Q4 profitability demonstrated scalability of the business more margins of 40% and an adj. EBIT margin close to 17%. Q4 orders declined qoq as expected. The company already in higher order levels are being registered in Q1 again.

SÜSS will **release its annual report and guidance for 2023 on March 31**, next week. Preliminary FY 2022 results were already issued earlier in the year. We adjust our 2022 estimates upwards somewhat as we had not yet incorporated a positive one-off amounting to EUR 2.8m resulting from the liquidation of its US subsidiary. However, it is worth mentioning that SÜSS should have recorded somewhat higher currency-related losses than usual last year, to the tune of a low single-digit million. As these should more or less offset the positive one-time effect, the organic EBIT margin should be in the ballpark of the reported EBIT margin (WRe 10.5%).

The expectation of significant sales growth in 2023 remains unchanged and is well underpinned: ~70% of the record order backlog of EUR 345m is expected to turn into revenues in 2023. On top come sales with low lead times (service + spare parts and microoptics) of ~EUR 80m combined and orders for less automated tools received in H1. With some caution baked into the forecast, we assume that SÜSS will provide a guidance range (in a ballpark of EUR 320–360m) that covers the consensus of EUR 333m and higher WRe forecasts of EUR 350m.


EBIT margin to rise further: Thanks to continued efficiency improvements, pricing effects (which took some months to become fully effective) and higher utilization, the **gross margin is expected to improve** to WRe ~37.5% in 2023. SÜSS already indicated an increase in opex in the next few years in light of the expected growth. We incorporated a ~10% rise in operating costs and **derive an EBIT-margin projection of 12.9%** (excluding currency effects seen in 2022). However, we **would not be surprised if the initial guidance remains below this level** as SÜSS is likely to take a conservative stance with the potential for a lower top-line midpoint and also some uncertainties on the timing of cost increases. Generally, the **2025 EBIT-margin target of 15% should, however, be confirmed** once again. With **valuation still attractive** and **clear upside to the PT of EUR 30**, the **Buy** rating is maintained and SÜSS remains a favourite pick.

Changes in	Estir	nates:						Comment on Changes:
FY End: 31.12. in EUR m		2022e (old)	+ / -	2023e (old)	+ / -	2024e (old)	+ / -	 Positive one-off mentioned above (EUR 2.8m) factored into the 2022 estimates
Sales EBIT		295.0 27.9	1.7 % 12.4 %	350.0 45.0	0.0 % 0.0 %	375.0 53.3	0.0 % 0.0 %	

2.5 -	nΛ	FY End: 31.12. in EUR m	CAGR (21-24e)	2018	2019	2020	2021	2022e	2023e	2024e
20 -	Nº Y	Sales	12.5 %	203.9	213.8	252.1	263.4	300.0	350.0	375.0
	1 M	Change Sales yoy		22.5 %	4.8 %	17.9 %	4.5 %	13.9 %	16.7 %	7.1 %
7.5 - m. m	ann	Gross profit margin		33.0 %	23.3 %	33.2 %	35.8 %	36.7 %	37.5 %	38.5 %
4. 7. 11 4	molect	EBITDA	28.8 %	15.7	-5.2	28.2	29.6	40.7	55.0	63.3
15 - Mr Mary War , m	MW	EBIT	33.2 %	10.9	-13.8	20.4	22.6	31.4	45.0	53.3
		Margin		5.3 %	-6.4 %	8.1 %	8.6 %	10.5 %	12.9 %	14.2 %
2.5 - V Wy V		EBIT adj.		10.9	0.5	23.0	22.6	28.6	45.0	53.3
10 - W		Margin		5.3 %	0.2 %	9.1 %	8.6 %	9.5 %	12.9 %	14.2 %
		Net income	32.9 %	4.8	-16.3	12.3	16.0	21.9	31.6	37.6
05/22 07/22 09/22 11/ Süss Microtec SE CDA		EPS	32.9 %	0.25	-0.85	0.65	0.84	1.15	1.65	1.97
- Suss Microtec SE - CDA	(normalised)	EPS adj.	32.9 %	0.69	-0.11	0.78	0.84	1.15	1.65	1.97
Rel. Performance vs CD	۵ΔΧ۰	DPS	16.0 %	0.00	0.00	0.00	0.16	0.16	0.25	0.25
		Dividend Yield		n.a.	n.a.	n.a.	0.7 %	0.8 %	1.2 %	1.2 %
1 month:	0.2 %	FCFPS		-0.26	-1.93	2.47	0.77	0.66	1.34	0.79
6 months:	45.5 %	FCF / Market cap		-2.0 %	-19.8 %	19.2 %	3.2 %	3.3 %	6.7 %	4.0 %
Year to date:	23.5 %	EV / Sales		1.1 x	1.0 x	0.9 x	1.6 x	1.2 x	0.9 x	0.8 x
Trailing 12 months:	17.3 %	EV / EBITDA		14.8 x	n.a.	8.2 x	14.5 x	8.5 x	5.9 x	4.9 x
5		EV / EBIT		21.4 x	n.a.	11.4 x	19.1 x	11.0 x	7.2 x	5.9 x
Company events:		P/E		53.5 x	n.a.	19.8 x	28.6 x	17.5 x	12.2 x	10.2 x
31.03.23	FY 2022	FCF Potential Yield		2.3 %	-4.8 %	13.8 %	5.4 %	8.3 %	12.1 %	14.3 %
11.05.23	Q1	Net Debt		-23.1	24.0	-13.9	-28.4	-37.9	-60.4	-70.8
31.05.23	AGM	ROCE (NOPAT)		4.5 %	n.a.	9.3 %	13.0 %	16.7 %	22.7 %	24.5 %
03.08.23	Q2	Guidance: 2	2022: Sales: c	a. 300m; EB	IT 10-11%					

Malte Schaumann mschaumann@warburg-research.com +49 40 309537-170






Company Background

- Globally leading manufacturer of systems for the MEMS, advanced packaging, 3D IC and LED niche markets with the product segments lithography (mask aligner,coater), bonder and equipment to clean photomasks.
- MEMS integrate electronic and mechanical components. Fields of application are e.g. pressure sensors (e.g. in tyre pressure control systems) or position and acceleration sensors (e.g. smartphones, tablet PCs).
- Advanced packaging is a special packaging process used as an alternative to the classic wire bonding ("flip chip") for semiconductors
 where these are directly bonded to the substrate without wire connections.
- 3D packaging is a solution to the increasingly difficult ongoing structural downsizing of semiconductors. CMOS image sensors are an early field of application. This market offers enormous growth potential for SÜSS.
- The majority of production is located at two sites in Germany (Garching, Sternenfels) which offer ample capacity for anticipated growth.
 SÜSS has ca. 900 employees.

Competitive Quality

- SÜSS consistently focuses on the core topics (precision, reliability and low total cost of ownership) in all segments and gears the products to the customers' needs.
- The 60-year company history and the consistently high product quality have firmly established SÜSS as a brand-name in the addressed markets.
- This and the global service network make the company a preferred supplier for production equipment in particular.
- As the respective markets have a niche character, SÜSS usually only has to face moderate competition and rarely has to compete with the major suppliers of the sector.
- This combined with the high product complexity poses a major barrier to market entry and secures the company a leading position in the respective markets.





DCF model														
	Detaile	d forecas	t period				٦	Fransition	al period					Term. Value
Figures in EUR m	2022e	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	
Sales	300.0	350.0	375.0	401.3	425.3	450.8	473.4	497.1	516.9	537.6	559.1	570.3	581.7	
Sales change	13.9 %	16.7 %	7.1 %	7.0 %	6.0 %	6.0 %	5.0 %	5.0 %	4.0 %	4.0 %	4.0 %	2.0 %	2.0 %	2.0 %
EBIT	31.4	45.0	53.3	60.2	63.8	67.6	71.0	74.6	77.5	80.6	83.9	85.5	87.3	
EBIT-margin	10.5 %	12.9 %	14.2 %	15.0 %	15.0 %	15.0 %	15.0 %	15.0 %	15.0 %	15.0 %	15.0 %	15.0 %	15.0 %	
Tax rate (EBT)	29.2 %	29.4 %	29.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	
NOPAT	22.2	31.8	37.6	43.0	45.6	48.4	50.8	53.3	55.4	57.7	60.0	61.2	62.4	
Depreciation	9.3	10.0	10.0	12.0	11.9	12.6	13.3	13.9	14.5	15.1	15.7	16.0	16.3	
in % of Sales	3.1 %	2.9 %	2.7 %	3.0 %	2.8 %	2.8 %	2.8 %	2.8 %	2.8 %	2.8 %	2.8 %	2.8 %	2.8 %	
Changes in provisions	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Change in Liquidity from														
- Working Capital	7.1	4.4	20.9	3.3	7.5	7.9	7.0	7.3	6.2	6.4	6.7	3.5	3.5	
- Capex	11.6	11.6	11.5	22.8	12.8	13.5	14.2	14.9	15.5	16.1	16.8	17.1	17.5	
Capex in % of Sales	3.9 %	3.3 %	3.1 %	3.2 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	12.8	25.8	15.2	28.9	37.3	39.5	42.8	45.0	48.2	50.2	52.2	56.6	57.7	59
PV of FCF	13.3	24.4	13.1	22.8	26.8	26.0	25.7	24.6	24.0	22.8	21.6	21.4	19.9	267
share of PVs		9.20 %						42.60) %					48.20 %
Model parameter							Valuat	ion (m)						
Derivation of WACC:			Derivation	of Beta:			Presen	t values 20	034e	28	37			
								al Value		26				
Debt ratio	4.00 %		Financial S	•		1.10		ial liabilitie		1	8			
Cost of debt (after tax)	2.9 %		Liquidity (s	hare)		1.30		n liabilities			5			
Market return	8.25 %		Cyclicality			1.60	Hybrid	•			0			
Risk free rate	2.75 %		Transpare	ncy		1.10		y interest			0			
			Others			1.40		val. of inv	estments		0		()	40.4
							Liquidit	y		2	7	No. of sha	. ,	19.1

Sensitivity Value per Share (EUR)

WACC

		Terminal C	Growth								Delta EBIT	-margin					
Beta	WACC	1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.49	10.6 %	25.69	25.97	26.26	26.58	26.91	27.26	27.64	1.49	10.6 %	23.46	24.50	25.54	26.58	27.62	28.66	29.70
1.39	10.1 %	27.22	27.55	27.90	28.27	28.66	29.08	29.53	1.39	10.1 %	24.96	26.06	27.16	28.27	29.37	30.47	31.58
1.35	9.9 %	28.05	28.41	28.79	29.20	29.63	30.09	30.58	1.35	9.9 %	25.78	26.92	28.06	29.20	30.33	31.47	32.61
1.30	9.6 %	28.94	29.33	29.74	30.19	30.66	31.17	31.71	1.30	9.6 %	26.67	27.84	29.01	30.19	31.36	32.53	33.71
1.25	9.4 %	29.88	30.30	30.76	31.25	31.77	32.32	32.93	1.25	9.4 %	27.61	28.82	30.03	31.25	32.46	33.67	34.88
1.21	9.1 %	30.88	31.35	31.85	32.38	32.95	33.57	34.24	1.21	9.1 %	28.62	29.87	31.13	32.38	33.64	34.89	36.14
1.11	8.6 %	33.10	33.66	34.27	34.92	35.62	36.38	37.20	1.11	8.6 %	30.88	32.22	33.57	34.92	36.26	37.61	38.96

Equity Value

577

Value per share (EUR)

30.19

1.30

Growth estimate below mid- to long-term ambition of SÜSS

• Sustainable EBIT margin of 15% anticipated...

9.62 %

Beta



Free Cash Flow Value Potential

Warburg Research's valuation tool "FCF Value Potential" reflects the ability of the company to generate sustainable free cash flows. It is based on the "FCF potential" - a FCF "ex growth" figure - which assumes unchanged working capital and pure maintenance capex. A value indication is derived via the perpetuity of a given year's "FCF potential" with consideration of the weighted costs of capital. The fluctuating value indications over time add a timing element to the DCF model (our preferred valuation tool).

in EUR m	2018	2019	2020	2021	2022e	2023e	2024€
Net Income before minorities	4.8	-16.3	12.3	16.0	21.9	31.6	37.6
+ Depreciation + Amortisation	4.8	8.6	7.8	7.1	9.3	10.0	10.0
 Net Interest Income 	-0.1	-0.4	-0.4	-0.5	-0.3	-0.2	0.0
 Maintenance Capex 	2.5	2.7	2.7	2.7	2.7	2.7	2.7
+ Other	-2.0	0.0	14.2	2.6	0.0	0.0	0.0
= Free Cash Flow Potential	5.3	-10.0	32.0	23.4	28.8	39.1	44.9
FCF Potential Yield (on market EV)	2.3 %	-4.8 %	13.8 %	5.4 %	8.3 %	12.1 %	14.3 %
WACC	9.62 %	9.62 %	9.62 %	9.62 %	9.62 %	9.62 %	9.62 %
= Enterprise Value (EV)	232.5	210.4	232.3	430.1	346.4	323.8	313.4
= Fair Enterprise Value	54.7	n.a.	332.9	243.5	299.7	406.3	466.8
- Net Debt (Cash)	-33.8	-33.8	-33.8	-33.8	-43.2	-65.7	-76.2
- Pension Liabilities	5.3	5.3	5.3	5.3	5.3	5.3	5.3
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
 Market value of minorities 	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Market value of investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
= Fair Market Capitalisation	83.1	n.a.	361.3	271.9	337.6	466.7	537.6
Number of shares, average	19.1	19.1	19.1	19.1	19.1	19.1	19.1
= Fair value per share (EUR)	4.35	n.a.	18.90	14.23	17.66	24.42	28.12
premium (-) / discount (+) in %					-12.1 %	21.5 %	39.9 %
Sensitivity Fair value per Share (El	JR)						
12		n.a.	14.77	11.21	13.94	19.38	22.33
11	.62 % 3.86	n.a.	15.92	12.04	14.97	20.77	23.94
10	.62 % 4.08	n.a.	17.27	13.04	16.20	22.43	25.84
WACC 9	.62 % 4.35	n.a.	18.90	14.23	17.66	24.42	28.12
8	.62 % 4.69	n.a.	20.94	15.72	19.49	26.91	30.98
7	.62 % 5.11	n.a.	23.49	17.58	21.79	30.02	34.56
6	.62 % 5.65	n.a.	26.82	20.02	24.79	34.08	39.22

• Increasing sales and margins result in higher value indications in coming years



Valuation							
	2018	2019	2020	2021	2022e	2023e	2024e
Price / Book	1.8 x	1.5 x	1.8 x	2.9 x	2.2 x	1.9 x	1.6 x
Book value per share ex intangibles	6.42	5.52	5.92	6.95	7.85	9.34	11.06
EV / Sales	1.1 x	1.0 x	0.9 x	1.6 x	1.2 x	0.9 x	0.8 x
EV / EBITDA	14.8 x	n.a.	8.2 x	14.5 x	8.5 x	5.9 x	4.9 x
EV / EBIT	21.4 x	n.a.	11.4 x	19.1 x	11.0 x	7.2 x	5.9 x
EV / EBIT adj.*	21.4 x	445.7 x	10.1 x	19.1 x	12.1 x	7.2 x	5.9 x
P / FCF	n.a.	n.a.	5.2 x	31.2 x	30.7 x	15.0 x	25.3 x
P/E	53.5 x	n.a.	19.8 x	28.6 x	17.5 x	12.2 x	10.2 x
P / E adj.*	19.4 x	n.a.	16.5 x	28.6 x	17.5 x	12.2 x	10.2 x
Dividend Yield	n.a.	n.a.	n.a.	0.7 %	0.8 %	1.2 %	1.2 %
FCF Potential Yield (on market EV)	2.3 %	-4.8 %	13.8 %	5.4 %	8.3 %	12.1 %	14.3 %
*Adjustments made for: -							

Company Specific Items							
	2018	2019	2020	2021	2022e	2023e	2024e
Order entry Order backlog	191.0 0.0	219.2 93.2	281.1 120.1	335.6 193.3	445.0 338.3	0.0 0.0	0.0 0.0

COMMENT Published 22.03.2023 5




Consolidated profit and loss

Consolidated profit and loss							
In EUR m	2018	2019	2020	2021	2022e	2023e	2024e
Sales	203.9	213.8	252.1	263.4	300.0	350.0	375.0
Change Sales yoy	22.5 %	4.8 %	17.9 %	4.5 %	13.9 %	16.7 %	7.1 %
COGS	136.7	164.1	168.4	169.2	189.9	218.8	230.6
Gross profit	67.3	49.7	83.7	94.2	110.1	131.3	144.4
Gross margin	33.0 %	23.3 %	33.2 %	35.8 %	36.7 %	37.5 %	38.5 %
Research and development	18.3	20.2	19.8	22.1	25.0	29.0	31.0
Sales and marketing	21.9	22.9	23.5	24.9	28.0	30.0	31.0
Administration expenses	15.9	18.9	20.8	22.9	23.5	26.0	28.0
Other operating expenses	3.5	3.2	3.4	5.9	12.0	1.3	1.1
Other operating income	3.2	1.7	4.3	4.2	9.8	0.0	0.0
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	15.7	-5.2	28.2	29.6	40.7	55.0	63.3
Margin	7.7 %	-2.4 %	11.2 %	11.2 %	13.6 %	15.7 %	16.9 %
Depreciation of fixed assets	3.6	7.3	7.1	6.4	8.4	9.0	9.0
EBITA	12.1	-12.5	21.1	23.2	32.3	46.0	54.3
Amortisation of intangible assets	1.2	1.2	0.7	0.7	0.9	1.0	1.0
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	10.9	-13.8	20.4	22.6	31.4	45.0	53.3
Margin	5.3 %	-6.4 %	8.1 %	8.6 %	10.5 %	12.9 %	14.2 %
EBIT adj.	10.9	0.5	23.0	22.6	28.6	45.0	53.3
Interest income	0.0	0.0	0.0	0.0	0.1	0.0	0.2
Interest expenses	0.2	0.4	0.4	0.5	0.4	0.2	0.2
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	10.7	-14.1	20.0	22.1	31.1	44.8	53.3
Margin	5.3 %	-6.6 %	7.9 %	8.4 %	10.4 %	12.8 %	14.2 %
Total taxes	6.0	2.1	7.7	6.1	9.2	13.2	15.7
Net income from continuing operations	4.8	-16.3	12.3	16.0	21.9	31.6	37.6
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	4.8	-16.3	12.3	16.0	21.9	31.6	37.6
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	4.8	-16.3	12.3	16.0	21.9	31.6	37.6
Margin	2.3 %	-7.6 %	4.9 %	6.1 %	7.3 %	9.0 %	10.0 %
Number of shares, average	19.1	19.1	19.1	19.1	19.1	19.1	19.1
EPS	0.25	-0.85	0.65	0.84	1.15	1.65	1.97
EPS adj.	0.69	-0.11	0.78	0.84	1.15	1.65	1.97
*Adjustments made for:							

Guidance: 2022: Sales: ca. 300m; EBIT 10-11%


Financial Ratios

	2018	2019	2020	2021	2022e	2023e	2024e
	2018	2019	2020	2021	20226	20236	20246
Total Operating Costs / Sales	27.7 %	29.7 %	25.1 %	27.2 %	26.2 %	24.6 %	24.3 %
Operating Leverage	-1.0 x	n.a.	n.a.	2.3 x	2.8 x	2.6 x	2.6 x
EBITDA / Interest expenses	90.3 x	n.m.	66.6 x	63.5 x	101.8 x	275.0 x	316.6 x
Tax rate (EBT)	55.4 %	-15.2 %	38.3 %	27.5 %	29.5 %	29.5 %	29.5 %
Dividend Payout Ratio	0.0 %	0.0 %	0.0 %	19.1 %	13.9 %	15.1 %	12.7 %
Sales per Employee	231,740	228,174	263,139	237,760	260,870	291,667	300,000





Performance per Share



COMMENT Published 22.03.2023

- Gross margin - Total Operating Costs / Sales - EBIT margin

2021 2022e 2023e 2024e

2018 2019 2020


Consolidated balance sh



Consolidated balance sheet							
In EUR m	2018	2019	2020	2021	2022e	2023e	2024e
Assets							
Goodwill and other intangible assets	17.7	19.9	23.4	24.0	24.3	24.4	24.4
thereof other intangible assets	1.9	4.2	5.0	5.6	5.8	5.9	5.9
thereof Goodwill	15.7	15.7	18.3	18.4	18.4	18.4	18.4
Property, plant and equipment	26.2	33.9	40.4	44.5	46.6	48.1	49.6
Financial assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	43.9	53.8	63.7	68.5	70.9	72.5	74.0
Inventories	93.5	75.0	73.0	99.5	142.9	116.7	110.3
Accounts receivable	25.1	50.2	48.0	47.4	53.4	47.9	46.2
Liquid assets	30.7	10.3	40.8	52.1	58.7	81.3	91.0
Other short-term assets	6.4	10.6	5.9	11.6	10.2	10.2	10.2
Current assets	155.7	146.1	167.7	210.7	265.2	256.0	257.6
Total Assets	199.6	199.9	231.4	279.2	336.1	328.5	331.7
Liabilities and shareholders' equity							
Subscribed capital	19.1	19.1	19.1	19.1	19.1	19.1	19.1
Capital reserve	122.9	106.6	119.0	135.0	135.0	135.0	135.0
Retained earnings	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other equity components	-1.5	-0.3	-1.6	2.8	20.3	48.8	81.7
Shareholders' equity	140.4	125.4	136.5	156.9	174.4	202.9	235.8
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	140.4	125.4	136.5	156.9	174.4	202.9	235.8
Provisions	10.3	10.2	10.9	11.2	11.2	11.2	11.2
thereof provisions for pensions and similar obligations	5.1	6.0	6.4	5.3	5.3	5.3	5.3
Financial liabilities (total)	2.5	28.3	20.5	18.3	15.5	15.5	14.8
Short-term financial liabilities	1.0	10.4	1.4	1.2	1.2	1.2	1.2
Accounts payable	9.0	10.0	9.8	24.4	20.5	14.4	15.4
Other liabilities	37.3	26.0	53.7	68.4	114.5	84.5	54.5
Liabilities	59.1	74.5	94.9	122.3	161.7	125.6	95.9
Total liabilities and shareholders' equity	199.6	199.9	231.4	279.2	336.1	328.5	331.7

Financial Ratios

	2018	2019	2020	2021	2022e	2023e	2024e
Efficiency of Capital Employment							
Operating Assets Turnover	1.7 x	1.5 x	2.0 x	2.0 x	2.1 x	2.4 x	2.2 x
Capital Employed Turnover	1.7 x	1.4 x	2.1 x	2.1 x	2.2 x	2.5 x	2.3 x
ROA	10.9 %	-30.3 %	19.4 %	23.4 %	30.9 %	43.5 %	50.8 %
Return on Capital							
ROCE (NOPAT)	4.5 %	n.a.	9.3 %	13.0 %	16.7 %	22.7 %	24.5 %
ROE	3.6 %	-12.2 %	9.4 %	10.9 %	13.2 %	16.7 %	17.1 %
Adj. ROE	9.9 %	-1.6 %	11.4 %	10.9 %	13.2 %	16.7 %	17.1 %
Balance sheet quality							
Net Debt	-23.1	24.0	-13.9	-28.4	-37.9	-60.4	-70.8
Net Financial Debt	-28.2	18.0	-20.3	-33.8	-43.2	-65.7	-76.2
Net Gearing	-16.4 %	19.2 %	-10.2 %	-18.1 %	-21.7 %	-29.8 %	-30.0 %
Net Fin. Debt / EBITDA	n.a.						
Book Value / Share	7.3	6.6	7.1	8.2	9.1	10.6	12.3
Book value per share ex intangibles	6.4	5.5	5.9	7.0	7.9	9.3	11.1



7

90.0 %

80.0 %

70.0 %

60.0 %

50.0 %

40.0 %

30.0 %

20.0 %

10.0 %

0.0 %

2024e

Consolidated cash flow statement




In EUR m	2018	2019	2020	2021	2022e	2023e	2024e
Net income	4.8	-16.3	12.3	16.0	21.9	31.6	37.6
Depreciation of fixed assets	3.6	7.3	7.1	6.4	8.4	9.0	9.0
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	1.2	1.2	0.7	0.7	0.9	1.0	1.0
Increase/decrease in long-term provisions	0.2	0.1	0.4	-1.2	0.0	0.0	0.0
Other non-cash income and expenses	2.9	5.2	9.1	7.8	0.0	0.0	0.0
Cash Flow before NWC change	12.7	-2.4	29.5	29.7	31.2	41.6	47.6
Increase / decrease in inventory	-29.8	4.6	9.8	-29.5	-43.4	26.2	6.4
Increase / decrease in accounts receivable	-1.9	-25.0	2.1	1.9	-6.0	5.5	1.7
Increase / decrease in accounts payable	1.7	-8.0	13.7	22.3	42.2	-36.1	-29.0
Increase / decrease in other working capital positions	19.3	0.0	0.0	0.0	0.0	0.0	0.0
Increase / decrease in working capital (total)	-10.8	-28.4	25.6	-5.4	-7.1	-4.4	-20.9
Net cash provided by operating activities [1]	1.9	-30.8	55.1	24.3	24.1	37.2	26.7
Investments in intangible assets	0.6	3.4	1.1	1.2	1.1	1.1	1.0
Investments in property, plant and equipment	6.3	5.7	8.0	8.5	10.5	10.5	10.5
Payments for acquisitions	0.0	0.0	-3.3	0.0	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.1	0.0	0.0	0.0	0.0
Net cash provided by investing activities [2]	-6.9	-6.1	-11.2	-9.6	-11.6	-11.6	-11.5
Change in financial liabilities	-1.0	16.4	-13.3	-3.8	-2.8	0.0	-0.7
Dividends paid	0.0	0.0	0.0	0.0	-3.1	-3.1	-4.8
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net cash provided by financing activities [3]	-1.0	16.4	-13.3	-3.8	-5.9	-3.1	-5.5
Change in liquid funds [1]+[2]+[3]	-6.0	-20.5	30.7	10.9	6.7	22.5	9.7
Effects of exchange-rate changes on cash	0.2	0.1	-0.2	0.0	0.0	0.0	0.0
Cash and cash equivalent at end of period	30.7	10.3	40.8	51.7	58.7	81.3	91.0

Financial Ratios

	2018	2019	2020	2021	2022e	2023e	2024e
Cash Flow							
FCF	-5.0	-36.9	47.2	14.7	12.5	25.6	15.2
Free Cash Flow / Sales	-2.5 %	-17.3 %	18.7 %	5.6 %	4.2 %	7.3 %	4.1 %
Free Cash Flow Potential	5.3	-10.0	32.0	23.4	28.8	39.1	44.9
Free Cash Flow / Net Profit	-105.1 %	226.9 %	382.4 %	91.9 %	57.1 %	81.0 %	40.4 %
Interest Received / Avg. Cash	0.1 %	0.0 %	0.0 %	0.0 %	0.2 %	0.0 %	0.2 %
Interest Paid / Avg. Debt	5.8 %	2.5 %	1.7 %	2.4 %	2.4 %	1.3 %	1.3 %
Management of Funds							
Investment ratio	3.4 %	4.2 %	3.6 %	3.7 %	3.9 %	3.3 %	3.1 %
Maint. Capex / Sales	1.2 %	1.3 %	1.1 %	1.0 %	0.9 %	0.8 %	0.7 %
Capex / Dep	143.2 %	105.6 %	117.1 %	136.4 %	124.7 %	116.0 %	115.0 %
Avg. Working Capital / Sales	39.5 %	46.1 %	37.9 %	33.0 %	30.7 %	28.0 %	29.5 %
Trade Debtors / Trade Creditors	278.4 %	501.1 %	487.7 %	194.0 %	260.5 %	332.6 %	300.0 %
Inventory Turnover	1.5 x	2.2 x	2.3 x	1.7 x	1.3 x	1.9 x	2.1 x
Receivables collection period (days)	45	86	69	66	65	50	45
Payables payment period (days)	24	22	21	53	39	24	24
Cash conversion cycle (Days)	222	210	151	155	146	137	164

CAPEX and Cash Flow in EUR m






2019

2020

FCF (m) - Free Cash Flow / Sales

Working Capital



COMMENT

Published 22.03.2023

2021 2022e 2023e 2024e

8



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <u>http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</u>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The **Warburg ESG Risk Score** is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.



Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.

2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.

3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.

4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.

5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a share of more than 5% of the equity capital of the analysed company.
- -2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research manage financial instruments, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide investment banking and/or investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
SÜSS MicroTec	5	http://www.mmwarburg.com/disclaimer/disclaimer en/DE000A1K0235.htm



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	159	74
Hold	46	21
Sell	7	3
Rating suspended	3	1
Total	215	100

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	44	86
Hold	6	12
Sell	0	0
Rating suspended	1	2
Total	51	100

PRICE AND RATING HISTORY SÜSS MICROTEC AS OF 22.03.2023



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



Matthias Rode Head of Equities

RESEARCH

Michael Heider Head of Research Henner Rüschmeier Head of Research Stefan Augustin Cap. Goods, Engineering Jan Bauer Renewables **Christian Cohrs** Industrials & Transportation Dr. Christian Ehmann BioTech, Life Science Felix Ellmann Software, IT Jörg Philipp Frey Retail, Consumer Goods Marius Fuhrberg Financial Services Mustafa Hidir Automobiles, Car Suppliers Fabio Hölscher

Automobiles, Car Suppliers **Philipp Kaiser** Real Estate, Construction

Head of Equity Sales. Germany

Head of Equity Sales, Germany

Marc Niemann

Klaus Schilling

Tim Beckmann

Lea Bogdanova

Jens Buchmüller

Scandinavia, Austria

Matthias Fritsch

Maximilian Martin

SALES TRADING

United Kingdom

Austria. Poland

Oliver Merckel Head of Sales Trading

Marcel Magiera

Bastian Quast

Elyaz Dust

Sales Trading

Sales Trading

Sales Trading

United Kingdom, Ireland

United Kingdom

INSTITUTIONAL EQUITY SALES

+49 40 309537-280 mheider@warburg-research.com +49 40 309537-270 hrueschmeier@warburg-research.com +49 40 309537-168 saugustin@warburg-research.com +49 40 309537-155 jbauer@warburg-research.com +49 40 309537-175 ccohrs@warburg-research.com +49 40 309537-167 cehmann@warburg-research.com +49 40 309537-120 fellmann@warburg-research.com +49 40 309537-258 jfrey@warburg-research.com +49 40 309537-185 mfuhrberg@warburg-research.com +49 40 309537-230 mhidir@warburg-research.com +49 40 309537-240 fhoelscher@warburg-research.com +49 40 309537-260 pkaiser@warburg-research.com

+49 40 3282-2660

+49 69 5050-7400

+49 40 3282-2665

+49 69 5050-7411

+49 69 5050-7415

+49 40 3282-2696

+49 69 5050-7413

+49 40 3282-2634

+49 40 3282-2702

+49 40 3282-2662

+49 40 3282-2701

edust@mmwarburg.com

mfritsch@mmwarburg.com

mmartin@mmwarburg.com

omerckel@mmwarburg.com

mmagiera@mmwarburg.com

bquast@mmwarburg.com

mniemann@mmwarburg.com

kschilling@mmwarburg.com

tbeckmann@mmwarburg.com

lbogdanova@mmwarburg.com

jbuchmueller@mmwarburg.com

+49 40 3282-2678

mrode@mmwarburg.com

Thilo Kleibauer Retail, Consumer Goods Hannes Müller Software, IT Andreas Pläsier Banks, Financial Services Malte Schaumann Technology **Oliver Schwarz** Chemicals, Agriculture Simon Stippig Real Estate, Telco Cansu Tatar Cap. Goods, Engineering Marc-René Tonn Automobiles, Car Suppliers Robert-Jan van der Horst

Technology Andreas Wolf Software, IT

+49 40 309537-257 tkleibauer@warburg-research.com +49 40 309537-255 hmueller@warburg-research.com +49 40 309537-246 aplaesier@warburg-research.com +49 40 309537-170 mschaumann@warburg-research.com +49 40 309537-250 oschwarz@warburg-research.com +49 40 309537-265 sstippig@warburg-research.com +49 40 309537-248 ctatar@warburg-research.com +49 40 309537-259 mtonn@warburg-research.com +49 40 309537-290 rvanderhorst@warburg-research.com +49 40 309537-140

awolf@warburg-research.com

Christopher Seedorf Switzerland +49 40 3282-2695 cseedorf@mmwarburg.com

Juliane Niemann Roadshow/Marketing

Jan-Philip Schmidt Sales Trading Sebastian Schulz Sales Trading Jörg Treptow Sales Trading jniemann@mmwarburg.com

+49 40 3282-2694

+49 40 3282-2682 jschmidt@mmwarburg.com +49 40 3282-2631 sschulz@mmwarburg.com +49 40 3282-2658 jtreptow@mmwarburg.com

MACRO RESEARC	н						
Carsten Klude Macro Research	+49 40 3282-2572 cklude@mmwarburg.com	Dr. Christian Jasperneite Investment Strategy	+49 40 3282-2439 cjasperneite@mmwarburg.com				
Our research can be found under:							
Warburg Research	research.mmwarburg.com/en/index.html	Refinitiv	www.refinitiv.com				
Bloomberg	RESP MMWA GO	Capital IQ	www.capitaliq.com				
FactSet	www.factset.com						
For access please contact:							
Andrea Schaper Sales Assistance	+49 40 3282-2632 aschaper@mmwarburg.com	Kerstin Muthig Sales Assistance	+49 40 3282-2703 kmuthig@mmwarburg.com				

